Antipsychotics for acute treatment of first episode schizophrenia

Creative-Tail-medicine.svg

Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.

[read the full story...]

Antipsychotic efficacy measured by real-world observational study

telescope-1082091_640

Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.

[read the full story...]

Schizophrenia, antipsychotics and quality of life: measuring the important things

photo-1436124396594-54d90bf69c66

Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.

[read the full story...]

Lithium for bipolar disorder: the best maintenance mood stabiliser protection against self-harm and suicide?

3779655817_65e65a76a4_o

Michael Ostacher provides a robust appraisal of a recent UK cohort study that suggests bipolar disorder patients taking lithium had reduced self-harm and unintentional injury rates, when compared with patients taking valproate, olanzapine or quetiapine.

[read the full story...]

Cochrane find no evidence for as required PRN medication for mental health inpatients

4711660113_49676b8c32_b

John Baker summarises an updated Cochrane review on ‘as required’ PRN medication regimens for seriously mentally ill people in hospital, which finds no randomised controlled trials that support this widely used intervention.

[read the full story...]

Antipsychotics for treatment-resistant schizophrenia

4655344761_e526e9afff_b

Murtada Alsaif summarises a recent network meta-analysis, which looks at the efficacy, acceptability and tolerability of antipsychotics for treatment-resistant schizophrenia.

[read the full story...]

Biological pathways, antipsychotics and schizophrenia

1622916980_ba3ea68e3e_b

Murtada Alsaif summarises a small cohort study that uses shotgun mass spectrometry proteomic profiling to unravel the molecular pathways involved with antipsychotic response in people with schizophrenia.

[read the full story...]

The antipsychotic drugs don’t work for anorexia nervosa

Refusing pills

Helen Bould appraises a recent meta-analysis of second-generation antipsychotics for anorexia nervosa, which finds that the drugs don’t lead to weight gain or improve eating disorder symptoms. So why are antipsychotics being used in this group of patients?

[read the full story...]

Switching antipsychotics in schizophrenia: the OPTiMiSE RCT

shutterstock_93305014

Tracey Roberts summarises a recent paper that reviews the existing literature concerned with switching antipsychotics in patients with schizophrenia, and goes on to present the ongoing OPTiMiSE RCT in this field, which is due to be published in 2016.

[read the full story...]

The more psychotic you are, the more benefit there is in taking antipsychotics

shutterstock_122223547

John Baker reviews a recent participant-level meta-analysis of six placebo-controlled studies, which looks at the initial severity of schizophrenia and the efficacy of antipsychotics including Olanzapine, Risperidone and Amisulpride.

[read the full story...]